Sang Jun Ha

Title: Innovations of Sang Jun Ha in DNA Vaccine Adjuvants.

Introduction

Sang Jun Ha is a notable inventor based in Pohang-si, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of DNA vaccine adjuvants. With a total of 2 patents, his work focuses on enhancing immune responses to combat various diseases.

Latest Patents

One of his latest patents involves the genes of the IL-12P40 subunit mutated to improve the activity of IL-12 and its use as a DNA vaccine adjuvant. This invention relates to a mutant gene of IL-12p40 that can produce IL-12 (interleukin 12) of both human and mouse origin with high activity. The expression vector containing this mutant gene is designed for use in DNA vaccine adjuvants. Specifically, the IL-12p40 mutant gene inhibits the secretion of IL-12p40 while allowing for the normal secretion of active IL-12p70. This is achieved by mutating the Asn-222 (human) or Asn-220 (mouse) amino acid of IL-12p40, which acts as a competitive inhibitor of the active form of IL-12, IL-12p70. The implications of this invention are significant, as the IL-12p40 mutant gene can be beneficial for DNA vaccination and gene therapy against various diseases, including AIDS, hepatitis C, hepatitis B, cancer, influenza, tuberculosis, and malaria, all of which require robust cellular immune responses for effective therapy.

Career Highlights

Sang Jun Ha is currently associated with Genexine Co., Ltd., where he continues to innovate in the field of biotechnology. His work has garnered attention for its potential applications in improving vaccine efficacy and therapeutic strategies.

Collaborations

He collaborates with notable colleagues, including Young Chul Sung and Sung Hee Lee, who contribute to his research endeavors.

Conclusion

Sang Jun Ha's innovative work in the field of DNA vaccine adjuvants showcases his commitment to advancing biotechnology for the treatment of critical diseases. His contributions are paving the way for future developments in vaccine technology and gene therapy.